Scientists at St. Jude Children's Research Hospital have found that they can reverse the effects of HNRNPH2-related ...

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a ...

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the ...

Biogen has agreed to acquire Apellis Pharmaceuticals after an extended negotiation process. The company also entered a collaboration with Alloy Therapeutics focused on antisense drug development using ...

According to SNS Insider, the global Antisense and RNAi Therapeutics Market was valued at USD 4.15 billion in 2023 and is expected to reach USD 18.48 billion by 2032, registering a compound annual ...

While studying Parkinson's disease, an international research group made a discovery which can improve industrial protein synthesis for therapeutic use. They managed to understand a novel function of ...

Scientists at St. Jude Children's Research Hospital have found they can reverse the effects of HNRNPH2-related ...

After a two-decade cycle of investor embrace and rejection, partnerships won and lost, failed clinical trials, layoffs, and rebuilds, Isis Pharmaceuticals has gained approval for the first ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...